Open-label extension study of ORKA-001 in moderate-to-severe plaque psoriasis

Phase 2, open-label, single-arm trial of orka-001 in plaque psoriasis, sponsored by Oruka Therapeutics. Primary endpoint: Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital… Planned start Sep 2026; status: authorised.